Floatz logo

Ixekizumab

Major Depressive Disorder

Icahn School of Medicine at Mount Sinaimonoclonal_antibodyPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

197 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Selegiline
Corium Innovations, Inc.
Phase 4BBB
Risperidone
Johns Hopkins University
Phase 4BBB
Edivoxetine
Eli Lilly and Company
Phase 3BBB
(1S,2R)-MILNACIPRAN
Allergan
Phase 4BBB
Brexpiprazole
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Ixekizumab is also rated in:

psoriasisActive
BB
Indicative · Phase 3
67 / 100
View asset →
psoriatic arthritisActive
BB
Indicative · Phase 3
64 / 100
View asset →
obesity disorderActive
B
Indicative · Phase 3
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →